Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer. Read more about Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Read more about Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Read more about Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline.
HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. Read more about HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Read more about Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials. Read more about Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. Read more about ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). Read more about PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. Read more about Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. Read more about Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
